Drugs / ex vivo-expanded HER2-specific T cells
ex vivo-expanded HER2-specific T cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01219907 | Jun 2012 → Jun 2014 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Withdrawn | No outcome recorded |
| Phase 1 | NCT00228358 | Jun 2003 → May 2011 | HER2 positive breast carcinoma, female breast carcinoma, non-small cell lung carcinoma, ovarian carcinoma +1 | University of Washington | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00791037 | Oct 2008 → Jul 2013 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ex vivo-expanded HER2-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00791037 ↗ |
| Modality | Cell therapy | “autologous ex vivo-expanded HER2-specific T cells” NCT00228358 ↗ |
| Route | Intravenous | “Laboratory-expanded T cells, given IV” NCT00228358 ↗ |